In the United States, the legality of medical marijuana varies in substantial ways from state to state. There are currently 29 US states with legal medical cannabis laws, as well as the District of Columbia. That leaves 21 states where medical marijuana is entirely prohibited. Marijuana cultivation, possession, and use in any form is illegal at the federal level.
Epidiolex is the first FDA-approved treatment in the U.S. that contains a purified drug substance derived from marijuana -- CBD -- and the first treatment for Dravet syndrome. In September 2018 the FDA rescheduled cannabidiol from a C-I controlled substance to a C-V controlled substance, meaning it has a proven medical use but a low risk of abuse. This change allows Epidiolex to be marketed in the U.S.
In a new short film produced by Patagonia, Harvesting Liberty, Michael Lewis, a veteran and hemp grower in Kentucky, shares his encounter with the DEA. In 2014, after the passage of the Farm Bill, Lewis was keen to plant hemp in Kentucky. “[But] the DEA didn’t agree that we had a right to plant the crop. They said they would arrest us,” he says in the film. The matter ended up in the Louisville court, where a judge sided with the farmers. “[We] took our seeds up, got them registered and certified, and threw them into the ground before anyone could change their mind,” Lewis says.
In December 2013, Uruguay became the first country to legalize growing, sale and use of cannabis. After a long delay in implementing the retail component of the law, in 2017 sixteen pharmacies were authorized to sell cannabis commercially. On June 19, 2018, the Canadian Senate passed a bill and the Prime Minister announced the effective legalization date as October 17, 2018. Canada is the second nation to legalize the drug.
Despite advances in pharmacologic and nonpharmacologic management, nausea and vomiting (N/V) remain distressing side effects for cancer patients and their families. Dronabinol, a synthetically produced delta-9-THC, was approved in the United States in 1986 as an antiemetic to be used in cancer chemotherapy. Nabilone, a synthetic derivative of delta-9-THC, was first approved in Canada in 1982 and is now also available in the United States. Both dronabinol and nabilone have been approved by the U.S. Food and Drug Administration (FDA)for the treatment of N/V associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetic therapy. Numerous clinical trials and meta-analyses have shown that dronabinol and nabilone are effective in the treatment of N/V induced by chemotherapy.[25-28] The National Comprehensive Cancer Network Guidelines recommend cannabinoids as breakthrough treatment for chemotherapy-related N/V. The American Society for Clinical Oncology (ASCO) antiemetic guidelines updated in 2017 recommends that the FDA-approved cannabinoids, dronabinol or nabilone, be used to treat N/V that is resistant to standard antiemetic therapies.
Three controlled trials demonstrated that oral THC has variable effects on appetite stimulation and weight loss in patients with advanced malignancies and human immunodeficiency virus (HIV) infection. One study evaluated the efficacy of dronabinol alone or with megestrol acetate compared with that of megestrol acetate alone for managing cancer-associated anorexia. In this randomized, double-blind study of 469 adults with advanced cancer and weight loss, patients received 2.5 mg of oral THC twice daily, 800 mg of oral megestrol daily, or both. Appetite increased by 75% in the megestrol group and weight increased by 11%, compared with a 49% increase in appetite and a 3% increase in weight in the oral THC group after 8 to 11 weeks of treatment. These two differences were statistically significant. Furthermore, the combined therapy did not offer additional benefits beyond those provided by megestrol acetate alone. The authors concluded that dronabinol did little to promote appetite or weight gain in advanced cancer patients compared with megestrol acetate. However, a smaller, placebo-controlled trial of dronabinol in cancer patients demonstrated improved and enhanced chemosensory perception in the cannabinoid group—food tasted better, appetite increased, and the proportion of calories consumed as protein was greater than in the placebo recipients.
With respect to fiber, a “composite” is often defined as a material consisting of 30%–70% fiber and 70%–30% matrix (Bolton 1995). However, in North America particleboards and fiberboards, which generally contain less than 10% adhesive or matrix, are sometimes referred to as composites. This section addresses plastic-type composites. In plastics, fibers are introduced to improve physical properties such as stiffness, impact resistance, bending and tensile strength. Man-made fibers of glass, kevlar and carbon are most commonly used today, but plant fibers offer considerable cost savings along with comparable strength properties.
“Hemp” refers primarily to Cannabis sativa L. (Cannabaceae), although the term has been applied to dozens of species representing at least 22 genera, often prominent fiber crops. For examples, Manila hemp (abaca) is Musa textilis Née, sisal hemp is Agave sisalina Perrine, and sunn hemp is Crotolaria juncea L. Especially confusing is the phrase “Indian hemp,” which has been used both for narcotic Asian land races of C. sativa (so-called C. indica Lamarck of India) and Apocynum cannabinum L., which was used by North American Indians as a fiber plant. Cannabis sativa is a multi-purpose plant that has been domesticated for bast (phloem) fiber in the stem, a multi-purpose fixed oil in the “seeds” (achenes), and an intoxicating resin secreted by epidermal glands. The common names hemp and marijuana (much less frequently spelled marihuana) have been applied loosely to all three forms, although historically hemp has been used primarily for the fiber cultigen and its fiber preparations, and marijuana for the drug cultigen and its drug preparations. The current hemp industry is making great efforts to point out that “hemp is not marijuana.” Italicized, Cannabis refers to the biological name of the plant (only one species of this genus is commonly recognized, C. sativa L.). Non-italicized, “cannabis” is a generic abstraction, widely used as a noun and adjective, and commonly (often loosely) used both for cannabis plants and/or any or all of the intoxicant preparations made from them.
If you haven’t been bombarded with CBD marketing or raves about it from friends, get ready. This extract—which comes from either marijuana or its industrial cousin, hemp—is popping up everywhere. There are CBD capsules, tinctures, and liquids for vaping plus CBD-infused lotions, beauty products, snacks, coffee, and even vaginal suppositories. Already some 1,000 brands of CBD products are available in stores—and online in states that don’t have lenient cannabis laws. This is a tiny fraction of what’s to come: The CBD market is poised to exceed $1 billion by 2020, per the Chicago-based research firm Brightfield Group.
This law provides a framework for commercial industrial hemp production in Montana following approval by the federal government. Provisions added to the 2014 Farm Bill (Section 7606) defined industrial hemp under federal law and recognized state agricultural departments' authority to develop research pilot programs to study the growth, cultivation, and/or marketing of industrial hemp.
“Hemp is of high nutritional quality because it contains high amounts of unsaturated fatty acids… Linoleic acid and alpha-linolenic acid are the only two fatty acids that must be ingested and are considered essential to human health … In contrast to shorter-chain and more saturated fatty acids, these essential fatty acids do not serve as energy sources, but as raw materials for cell structure and as precursors for biosynthesis for many of the body’s regulatory biochemicals…”